Evidence map›Paper›PMID 23896972›Full record

Trial reportClinical research in cardiology : official journal of the German Cardiac Society2013

Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial.

Jochen Wöhrle, Fabian von Scheidt, Peter Schauwecker, Markus Wiesneth, Sinisa Markovic, Hubert Schrezenmeier, Vinzenz Hombach, Wolfgang Rottbauer, Peter Bernhardt

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00669227 (Intracoronary Stem Cell Therapy in Patients With Acute Myocardial Infarction - A Randomized, Double-blind, Placebo Controlled Trial), which is not on this map. Cited by 28 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00669227 phase2completednot on this map

Intracoronary Stem Cell Therapy in Patients With Acute Myocardial Infarction - A Randomized, Double-blind, Placebo Controlled Trial (SCAMI)

TypeinterventionalSponsorUniversity of UlmRan2005Enrolled42ConditionsAcute Myocardial Infarction, Coronary Artery DiseaseArmsautologous stem cells, placebo suspension
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Stem cell treatment for acute myocardial infarction.The Cochrane database of systematic reviews · 2015
    Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Stem cells therapy in acute myocardial infarction: a new era?Clinical and experimental medicine · 2021
    Review
  14. Review
  15. Review
  16. The role of stem cells in treating coronary artery disease in 2018.Indian journal of thoracic and cardiovascular surgery · 2018
    Review
  17. Regenerative Therapy for Cardiomyopathies.Journal of cardiovascular translational research · 2018
    Review
  18. Therapeutic Use of Stem Cells for Myocardial Infarction.Bioengineering (Basel, Switzerland) · 2018
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jochen WöhrleClinic for Internal Medicine II, University of Ulm, Ulm, Germany, jochen.woehrle@uniklinik-ulm.de.
Fabian von Scheidt
Peter Schauwecker
Markus Wiesneth
Sinisa Markovic
Hubert Schrezenmeier
Vinzenz Hombach
Wolfgang Rottbauer
Peter Bernhardt

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn patients with acute myocardial infarction (AMI), the number of transplanted autologous bone-marrow cells (BMC) has been linked to improvement in left ventricular ejection fraction (LVEF). Complete obstruction of myocardial microvasculature is indicated by microvascular obstruction (MO) in cardiac magnetic resonance imaging (CMR). We analyzed whether the number of transplanted cells and presence of MO were associated with improved LVEF in the double-blind, placebo-controlled, randomized intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial. METHODS AND

resultsPatients (N = 42) received study therapy mean 7 days after AMI. Median number of transplanted BMC was 324 × 10(6). CMR was performed prior to study therapy and annually up to 3 years and revealed no difference between BMC and placebo population. Patients treated with a cell number above the median experienced a significant improvement in LVEF compared with patients with cell number below the median 3.6 ± 3.4 versus -0.5 ± 6.4 % (difference 4.1, 95 % CI 0.2 to 8.1 %, p = 0.04) at 6 months. The difference in LVEF change between the groups remained with 3.8 % (p = 0.12) at 12 months, 4.5 % (p = 0.07) at 24 months and 5.6 % (p = 0.03) at 36 months. BMC treated patients without MO experienced a better improvement in LVEF compared with patients with MO at 6, 12, 24 and 36 months with 3.5, 5.3, 6.4 and 3.2 %.

conclusionsIn the randomized, placebo-controlled double-blind SCAMI trial improvement in LVEF up to 3 years was higher in BMC patients treated with a high cell number or without MO.

Indexed as

Bone Marrow TransplantationDouble-Blind MethodFollow-Up StudiesHumansMagnetic Resonance ImagingMicrocirculationMiddle AgedMyocardial InfarctionStem Cell TransplantationTime FactorsTreatment OutcomeVentricular Dysfunction, Left

Identifiers

PMID23896972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.